Latest News in the pharma Industry

Policy & Regulation

Expanded GXP compliance increases Concept's breadth of services

Expanded GXP compliance increases Concept's breadth of services

9 Feb 2018

Successful MHRA inspection at Dundee site confirms GLP accreditation for in vitro safety studies and bioanalysis.

Read more 
'Effective' hair loss treatment candidate advances to Phase IIa

'Effective' hair loss treatment candidate advances to Phase IIa

7 Feb 2018

German Medicines Agency sees potential in FOL-005 - a modified version of the endogenous protein, osteopontin - the green light for further studies.

Read more 
Sanofi, DNDi seek EMA review for sleeping sickness treatment

Sanofi, DNDi seek EMA review for sleeping sickness treatment

1 Feb 2018

Fexinidazole would be first all-oral treatment under investigation for both first and second stages of sleeping sickness, a fatal disease, endemic in Africa.

Read more 
Companies warned for selling unapproved opioid cessation products using deceptive claims

Companies warned for selling unapproved opioid cessation products using deceptive claims

26 Jan 2018

The companies have 15 days to respond to the FDA and FTC.

Read more 
Shire receives FDA approval for tech transfer of Cinryze

Shire receives FDA approval for tech transfer of Cinryze

24 Jan 2018

Commercial manufacturing of Cinryze drug product in Vienna to begin in the first quarter of 2018.

Read more 
Promacta receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia

Promacta receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia

4 Jan 2018

Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%.

Read more 
Novartis Kisqali receives FDA Breakthrough Therapy designation

Novartis Kisqali receives FDA Breakthrough Therapy designation

3 Jan 2018

Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal women who received no prior endocrine therapy for adva...

Read more 
Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review

Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review

1 Jan 2018

If approved, Tafinlar + Mekinist expected to be the first adjuvant targeted therapy combination to demonstrate a significant clinical benefit in patients with a BRAF V600 mutation.

Read more 
ANVISA approves Biocon and Mylan's biosimilar Trastuzumab

ANVISA approves Biocon and Mylan's biosimilar Trastuzumab

29 Dec 2017

Libbs will commercialize the product in Brazil under the brand name Zedora.

Read more 
FDA approves first generic for Estrace Cream

FDA approves first generic for Estrace Cream

29 Dec 2017

Mylan now offers estradiol in four delivery methods.

Read more 
FDA accepts NDA filing for Epidiolex in the treatment of Lennox-Gastaut syndrome and Dravet syndrome

FDA accepts NDA filing for Epidiolex in the treatment of Lennox-Gastaut syndrome and Dravet syndrome

28 Dec 2017

The PDUFA goal date for completion of the FDA review of the Epidiolex NDA is 27 June 2018.

Read more 
Novartis drug Tasigna approved by FDA

Novartis drug Tasigna approved by FDA

28 Dec 2017

First and only CML therapy with Treatment-free Remission data in its label.

Read more